{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:33Z","timestamp":1753891233327,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070989"],"award-info":[{"award-number":["82070989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tuberculosis (TB) is a serious infectious disease that endangers human health, and TB becomes more difficult in eradiation due to its multidrug resistance (MDR). The objective of this research was to identify novel targets for treating TB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 2-fold serial dilution method was used to determine minimal inhibitory concentrations (MIC) of compound M6 against <jats:italic>Mycobacterium smegmatis<\/jats:italic> (<jats:italic>M. smegmatis<\/jats:italic>). Compound M6 was subjected to reverse molecular docking with seven <jats:italic>Mycobacterium tuberculosis<\/jats:italic> proteins, and the best binding protein with the highest LibDock score was evaluated. The target protein with the highest score was purified through prokaryotic expression. Isolated target proteins were investigated for the enzyme activities and for the kinetic effect of compound M6 by absorbance detection. Subsequently, the CRISPR\/Cas9 technology was employed to inhibit target gene expression for detecting MIC changes. Finally, potential targets were evaluated for the effect of the compound M6 in bacteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The MIC values of compound M6 against <jats:italic>M. smegmatis<\/jats:italic> were 32\u2009\u03bcg\/mL. The results from reverse molecular docking show that IspD has the highest LibDock score of 142.50, followed by Rv0674, IspF, and Dxr, with docking scores of 110.762, 71.6955, and 57.7446, respectively. IspD is a key enzyme in the 2-C-methyl-D-erythritol 4-phosphate pathway of MTB. The aKi and Ki values of M6 for the substrate MEP are 609.58\u2009\u03bcM and 81.33\u2009\u03bcM. For CTP, the aKi and Ki values are 657.89\u2009\u03bcM and 40.07\u2009\u03bcM. With tetracycline inducing CRISPR\/Cas9 to suppress the expression of IspD, the MIC value of M6 against IspD went down significantly from 32\u2009\u03bcg\/mL to 4\u2009\u03bcg\/mL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IspD is a novel target of the compound M6 for treating TB.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2024.1461227","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:26:44Z","timestamp":1731497204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of IspD as a novel target for tuberculosis treatment using compound M6"],"prefix":"10.3389","volume":"15","author":[{"given":"Lijun","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiyun","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiancai","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hetian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"12238","DOI":"10.1038\/s41598-018-30209-y","article-title":"Investigation of the anti-TB potential of selected propolis constituents using a molecular docking approach","volume":"8","author":"Ali","year":"2018","journal-title":"Sci. Rep."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/molecules28031403","article-title":"The multifaceted MEP pathway: towards new therapeutic perspectives","volume":"28","author":"Allamand","year":"2023","journal-title":"Molecules"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1039\/C3NP70124G","article-title":"Methylerythritol 4-phosphate (MEP) pathway metabolic regulation","volume":"31","author":"Banerjee","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"9580","DOI":"10.1021\/acs.joc.8b00686","article-title":"Synthesis and evaluation of Fluoroalkyl Phosphonyl analogues of 2-C-Methylerythritol phosphate as substrates and inhibitors of IspD from human pathogens","volume":"83","author":"Bartee","year":"2018","journal-title":"J. Organomet. Chem."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol. Ther."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/17460441.2021.1858793","article-title":"The latest automated docking technologies for novel drug discovery","volume":"16","author":"Caballero","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.4103\/0253-7613.117765","article-title":"Bedaquiline: a new drug approved for treatment of multidrug-resistant tuberculosis","volume":"45","author":"Deoghare","year":"2013","journal-title":"Indian J. Pharm."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"12274","DOI":"10.1080\/21655979.2021.2006966","article-title":"Exploration of the mechanism of luteolin against ischemic stroke based on network pharmacology, molecular docking and experimental verification","volume":"12","author":"Dong","year":"2021","journal-title":"Bioengineered"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"8922","DOI":"10.1128\/JB.00925-07","article-title":"Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug development","volume":"189","author":"Eoh","year":"2007","journal-title":"J. Bacteriol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular docking and structure-based drug design strategies","volume":"20","author":"Ferreira","year":"2015","journal-title":"Molecules"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1021\/acs.chemrev.6b00537","article-title":"The Methylerythritol phosphate pathway to isoprenoids","volume":"117","author":"Frank","year":"2017","journal-title":"Chem. Rev."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejphar.2012.08.012","article-title":"Identification and validation of a novel lead compound targeting 4-diphosphocytidyl-2-C-methylerythritol synthetase (IspD) of mycobacteria","volume":"694","author":"Gao","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103534","DOI":"10.1016\/j.bioorg.2019.103534","article-title":"New potential drug leads against MDR-MTB: A short review","volume":"95","author":"Gatadi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","article-title":"A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering","volume":"65","author":"Hillary","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.tim.2020.04.010","article-title":"Immunometabolism during Mycobacterium tuberculosis infection","volume":"28","author":"Howard","year":"2020","journal-title":"Trends Microbiol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11103-008-9297-5","article-title":"Chloroplast localization of methylerythritol 4-phosphate pathway enzymes and regulation of mitochondrial genes in ispD and ispE albino mutants in Arabidopsis","volume":"66","author":"Hsieh","year":"2008","journal-title":"Plant Mol. Biol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2174\/1385272819666140501001101","article-title":"Koppisch.Synthetic routes to Methylerythritol phosphate pathway intermediates and downstream isoprenoids","volume":"18","author":"Jarchow-Choy","year":"2014","journal-title":"Curr. Org. Chem."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1080\/07391102.2022.2107573","article-title":"Molecular dynamics and docking studies on potentially active natural phytochemicals for targeting SARS-CoV-2 main protease","volume":"41","author":"Karakkadparambil Sankaran","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"p. CD012768","DOI":"10.1002\/14651858.CD012768.pub3","article-title":"Xpert MTB\/RIF ultra and Xpert MTB\/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults","volume":"2021","author":"Kohli","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/jac\/dkt308","article-title":"Determining accurate vancomycin MIC values for methicillin-resistant Staphylococcus aureus by the microdilution method","volume":"69","author":"Lepe","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pep.2011.03.013","article-title":"High level expression, purification and characterization of active fusion human C1q and tumor necrosis factor related protein 2 (hCTRP2) in Escherichia coli","volume":"79","author":"Li","year":"2011","journal-title":"Protein Expr. Purif."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/resp.13393","article-title":"Drug resistance mechanisms and drug susceptibility testing for tuberculosis","volume":"23","author":"Miotto","year":"2018","journal-title":"Respirology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2217\/fmb.13.85","article-title":"Martin.TMC207 becomes bedaquiline, a new anti-TB drug","volume":"8","author":"Palomino","year":"2013","journal-title":"Future Microbiol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1128\/AAC.00307-09","article-title":"Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus","volume":"53","author":"Patel","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijmy.ijmy_217_22","article-title":"Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review","volume":"12","author":"Putra","year":"2023","journal-title":"Int. J. Mycobacteriol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"831436","DOI":"10.3389\/fmed.2022.831436","article-title":"A novel role of IL13Ralpha2 in the pathogenesis of proliferative vitreoretinopathy","volume":"9","author":"Qi","year":"2022","journal-title":"Front Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/prot.20217","article-title":"FlexX-scan: fast, structure-based virtual screening","volume":"57","author":"Schellhammer","year":"2004","journal-title":"Proteins"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"24027","DOI":"10.1038\/srep24027","article-title":"Computational approach towards exploring potential anti-chikungunya activity of selected flavonoids","volume":"6","author":"Seyedi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"p. CD013694","DOI":"10.1002\/14651858.CD013694.pub2","article-title":"Xpert MTB\/RIF and Xpert ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms","volume":"2021","author":"Shapiro","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1093\/nar\/gkw625","article-title":"Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system","volume":"44","author":"Singh","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2174\/1389201033489784","article-title":"The methylerythritol phosphate pathway and its significance as a novel drug target","volume":"4","author":"Testa","year":"2003","journal-title":"Curr. Pharm. Biotechnol."},{"year":"2021","key":"ref36"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1461227\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:26:46Z","timestamp":1731497206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1461227\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":36,"alternative-id":["10.3389\/fmicb.2024.1461227"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1461227","relation":{},"ISSN":["1664-302X"],"issn-type":[{"type":"electronic","value":"1664-302X"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"article-number":"1461227"}}